Protein News and Research

RSS

Proteins are complex molecules that are made up of amino acids. They can be found in every cell in the body, and carry out vital processes that keep human beings alive. Mutations in proteins can lead to a multitude of diseases, the most common being cancer.

Amorfix Life Sciences achieves 100% specificity in using EP-vCJD Blood Screening Assay

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases, today announced it has achieved 100% specificity (no reproducible false positive results) upon testing 19,000 blood donations for variant Creutzfeldt-Jakob Disease ("vCJD") with the EP-vCJD(TM) Blood Screening Assay at l'Etablissement Français du Sang de Pyrénées Méditerrannée ("EFS-PM") in Montpellier, France.

29 Oct 2009

Promedior granted European Orphan Medicinal Product Designation for PRM-151

Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today that the European Commission has granted Orphan Medicinal Product Designation to its lead drug candidate PRM-151 for use in the prevention of scarring post glaucoma filtration surgery.

29 Oct 2009

Third-quarter fiscal 2009 results announced by Curis

Curis, Inc., a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today reported its financial results for the third quarter ended September 30, 2009.

29 Oct 2009

Genetic mutations may put individuals at increased risk for fungal infections

New research has identified two genetic mutations that may put individuals at increased risk for fungal infections. The research focused on patients with severe fungal infections (primarily of the genus Candida), but the findings may also have implications for patients who have more common mild infections.

29 Oct 2009

CytRx study reveals potential of molecular chaperones in design of anti-aging pharmaceuticals

CytRx Corporation, a biopharmaceutical company and a leader in molecular chaperone regulation technology, today announced that a paper published in the peer-reviewed journal Gerontology concluded that molecular chaperone amplification may represent a “significant strategy” in the future design of anti-aging pharmaceuticals.

29 Oct 2009

Effects of head injuries on players in the NFL: House Judiciary Committee's call to experts

The House Judiciary Committee today called upon national experts and stakeholders in the fields of science and sport to better understand the effects of head injuries on players in the National Football League (NFL). Nationally recognized sports physician and neurosurgeon, Julian E. Bailes, M.D. was called to provide expert testimony based on decades of research detailing how repetitive head trauma on the field leads to long-term neurological damage among athletes.

29 Oct 2009

Fresenius Kabi to license its proprietary HESylation Technology to Octapharma

Octapharma Group and Fresenius Kabi have signed a License, Development and Supply Agreement regarding the use of Fresenius Kabi's HESylation® Technology to develop a HESylated recombinant protein.

29 Oct 2009

Long-term effects of statin therapy could lead to transient or permanent cognitive impairment

Besides their tremendous value in treating high cholesterol and lowering the risk of heart disease, statins have also been reported to potentially lower the risks of other diseases, such as dementia. However, a study in the October Journal of Lipid Research finds that similar statin drugs can have profoundly different effects on brain cells -both beneficial and detrimental.

29 Oct 2009

CNS Protein Therapeutics changes its corporate name to Amarantus Therapeutics

CNS Protein Therapeutics, Inc., a privately held biotechnology company developing first-in-class disease–modifying treatments that address the underlying cause of cell death associated with a wide range of diseases, has completed a corporate name change to Amarantus Therapeutics, Inc. (“Amarantus”) and appointed prominent biotechnology industry executive, Martin D. Cleary, as Chief Executive Officer.

29 Oct 2009

CTE cases are misdiagnosed as Alzheimer's disease, says CSTE researchers

The Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine (BUSM) announced today that a recently deceased member of the NFL Hall of Fame suffered from the degenerative brain disease Chronic Traumatic Encephalopathy (CTE) when he died, becoming the 10th former NFL player diagnosed with the disease.

29 Oct 2009

Antibiotic effects of pumpkin may help fight yeast infections

The skin of that pumpkin you carve into a Jack-o'-Lantern to scare away ghosts and goblins on Halloween contains a substance that could put a scare into microbes that cause millions of cases of yeast infections in adults and infants each year.

29 Oct 2009

Recipients of the second round of funding under CLL/SLL Research Initiative announced by LRF

The Lymphoma Research Foundation (LRF) is pleased to announce that David Frank, MD, PhD of the Dana-Farber Cancer Institute and Thomas Kipps, MD, PhD, Moores Cancer Center, University of California, San Diego are the recipients of the second round of funding under the Foundation's Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Research Initiative.

29 Oct 2009

Pregnant women with symptoms of depression have a stronger biological reaction to the seasonal flu vaccine

Pregnant women with significant symptoms of depression tend to have a stronger biological reaction to the seasonal flu vaccine than do women with lower depression levels, according to a new study.

29 Oct 2009

Gene variant may be the cause for bad driving: UC Irvine neuroscientists

Bad drivers may in part have their genes to blame, suggests a new study by UC Irvine neuroscientists.

29 Oct 2009

Berkeley HeartLab enters into collaborative agreement

Berkeley HeartLab (BHL), a subsidiary of Celera Corporation, announced today that it has entered into collaborative agreements with Geisinger Medical Center and Proven Diagnostics, a clinical laboratory service recently launched by Geisinger Health System.

29 Oct 2009

Pure Protein develops soluble Class II human leukocyte antigens

Pure Protein, L.L.C., a biopharmaceutical company specializing in diagnostic and therapeutic reagents for use in immunology research and development, has announced that Chief Scientist William Hildebrand, Ph.D., and his team, have developed soluble Class II human leukocyte antigens (HLA). This represents a significant technology breakthrough that can dramatically impact multiple pharmaceutical and medical sectors and has enormous market potential. Autoimmune disease is a key area of interest for HLA research and product development.

28 Oct 2009

DSM Biomedical announces new non-biofouling coating technology for medical applications

DSM Biomedical, a global leader in biomedical materials, today announced the development of VitroStealth™, a breakthrough non-biofouling (NBF) coating technology. Specifically developed to combine state of the art non-biofouling properties with high durability and fast processing, VitroStealth™ coating is scratch resistant and reduces unwanted protein absorption and cellular adhesion on surfaces.

28 Oct 2009

Arrayit sells NanoPrint Microarrayer system to CENAT

Arrayit Corporation today announced the sale of a system to the Center of Excellence for Nucleic Acid-Based Technologies (CENAT) in Poznan, Poland. The Arrayit NanoPrint Microarrayer will be used by CENAT for scientific and medical collaborations throughout the prosperous democracy.

28 Oct 2009

Scientists test rapamycin's effectiveness at rescuing impaired nerve cells

Johns Hopkins scientists report having used a commercially available drug to successfully "rescue" animal brain cells that they had intentionally damaged by manipulating a newly discovered gene that links susceptibility genes for schizophrenia and autism.

28 Oct 2009

Successful partnership between Mercury Therapeutics and CreaGen Biosciences highlighted

The recent licensing deal between Mercury Therapeutics and Debiopharm showcases the highly successful partnership between Mercury Therapeutics and CreaGen Biosciences, said CreaGen in a statement released today.

28 Oct 2009

Protein News and Research

Further Reading

Amorfix Life Sciences achieves 100% specificity in using EP-vCJD Blood Screening Assay

Promedior granted European Orphan Medicinal Product Designation for PRM-151

Third-quarter fiscal 2009 results announced by Curis

Genetic mutations may put individuals at increased risk for fungal infections

CytRx study reveals potential of molecular chaperones in design of anti-aging pharmaceuticals

Effects of head injuries on players in the NFL: House Judiciary Committee's call to experts

Fresenius Kabi to license its proprietary HESylation Technology to Octapharma

Long-term effects of statin therapy could lead to transient or permanent cognitive impairment

CNS Protein Therapeutics changes its corporate name to Amarantus Therapeutics

CTE cases are misdiagnosed as Alzheimer's disease, says CSTE researchers

Antibiotic effects of pumpkin may help fight yeast infections

Recipients of the second round of funding under CLL/SLL Research Initiative announced by LRF

Pregnant women with symptoms of depression have a stronger biological reaction to the seasonal flu vaccine

Gene variant may be the cause for bad driving: UC Irvine neuroscientists

Berkeley HeartLab enters into collaborative agreement

Pure Protein develops soluble Class II human leukocyte antigens

DSM Biomedical announces new non-biofouling coating technology for medical applications

Arrayit sells NanoPrint Microarrayer system to CENAT

Scientists test rapamycin's effectiveness at rescuing impaired nerve cells

Successful partnership between Mercury Therapeutics and CreaGen Biosciences highlighted

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News